Literature DB >> 28101248

Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.

Shan Li1, Ting-Ting Feng2, Yang Guo1, Xianjun Yu1, Qiuyue Huang1, Liang Zhang1, Wei Tang1, Ying Liu1.   

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently characterized oncoprotein which is involved in the progression of several human malignancies. The present study aimed to investigate its biological function in human triple negative breast cancer (TNBC). The expression of CIP2A in TNBC cells was examined and it was observed that CIP2A was elevated in the TNBC cell line compared with poorly invasive breast cancer cells. CIP2A depletion in TNBC cell lines inhibited proliferation, and induced apoptosis and autophagy. In addition, CIP2A depletion inhibited invasion and migration of TNBC cells. Furthermore, CIP2A depletion downregulated Akt/mTOR/P70S6K phosphorylation. These results validate the role of CIP2A as a invasion-associated oncoprotein and established CIP2A as a promising therapeutic target of TNBC.

Entities:  

Keywords:  autophagy; cancerous inhibitor of protein phosphatase 2A; invasion; survival; triple negative breast cancer

Year:  2016        PMID: 28101248      PMCID: PMC5228275          DOI: 10.3892/ol.2016.5374

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation.

Authors:  J Wang; W Li; L Li; X Yu; J Jia; C Chen
Journal:  Int J Lab Hematol       Date:  2011-01-11       Impact factor: 2.877

3.  Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Zheng Hu; Fu-Qun Wu; Wei Li; Jinsong Liu; Guang-Biao Zhou
Journal:  Carcinogenesis       Date:  2013-11-30       Impact factor: 4.944

4.  c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.

Authors:  José P Vaqué; Belén Fernández-García; Pablo García-Sanz; Nuria Ferrandiz; Gabriel Bretones; Fernando Calvo; Piero Crespo; María C Marín; Javier León
Journal:  Mol Cancer Res       Date:  2008-02       Impact factor: 5.852

5.  Lymphatic and capillary invasion patterns in triple negative breast cancer.

Authors:  Sebnem Yaman; Berrak Gumuskaya; Cigdem Ozkan; Sercan Aksoy; Gulnur Guler; Kadri Altundag
Journal:  Am Surg       Date:  2012-11       Impact factor: 0.688

6.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Mhairi Copland; Joseph R Slupsky; Richard E Clark
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

7.  Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Authors:  Åslaug Helland; Michael S Anglesio; Joshy George; Prue A Cowin; Cameron N Johnstone; Colin M House; Karen E Sheppard; Dariush Etemadmoghadam; Nataliya Melnyk; Anil K Rustgi; Wayne A Phillips; Hilde Johnsen; Ruth Holm; Gunnar B Kristensen; Michael J Birrer; Richard B Pearson; Anne-Lise Børresen-Dale; David G Huntsman; Anna deFazio; Chad J Creighton; Gordon K Smyth; David D L Bowtell
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

8.  Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.

Authors:  Kyungsoo Ha; Warren Fiskus; Dong Soon Choi; Srividya Bhaskara; Leandro Cerchietti; Santhana G T Devaraj; Bhavin Shah; Sunil Sharma; Jenny C Chang; Ari M Melnick; Scott Hiebert; Kapil N Bhalla
Journal:  Oncotarget       Date:  2014-07-30

9.  ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation.

Authors:  Bin Liu; Mei Han; Rong-Hua Sun; Jun-Jie Wang; Yan-Ping Zhang; Di-Qun Zhang; Jin-Kun Wen
Journal:  Breast Cancer Res       Date:  2010-01-25       Impact factor: 6.466

10.  CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.

Authors:  Pietri Puustinen; Anna Rytter; Monika Mortensen; Pekka Kohonen; José M Moreira; Marja Jäättelä
Journal:  J Cell Biol       Date:  2014-03-03       Impact factor: 10.539

View more
  3 in total

1.  Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.

Authors:  Ming Zhao; Erin W Howard; Amanda B Parris; Zhiying Guo; Qingxia Zhao; Zhikun Ma; Ying Xing; Bolin Liu; Susan M Edgerton; Ann D Thor; Xiaohe Yang
Journal:  Oncotarget       Date:  2017-07-19

Review 2.  PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.

Authors:  Henan Zhao; Duojiao Li; Baojing Zhang; Yan Qi; Yunpeng Diao; Yuhong Zhen; Xiaohong Shu
Journal:  Molecules       Date:  2017-12-20       Impact factor: 4.411

3.  CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer.

Authors:  Melani Luque; Ion Cristóbal; Marta Sanz-Álvarez; Andrea Santos; Sandra Zazo; Pilar Eroles; Oriol Arpí; Ana Rovira; Joan Albanell; Juan Madoz-Gúrpide; Jesús García-Foncillas; Federico Rojo
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.